Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis.

Liu X, Jakubowski M, Hunt JL.

Am J Clin Pathol. 2011 Feb;135(2):245-52. doi: 10.1309/AJCP7FO2VAXIVSTP.

PMID:
21228365
2.

Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B.

Asaka S, Arai Y, Nishimura Y, Yamaguchi K, Ishikubo T, Yatsuoka T, Tanaka Y, Akagi K.

Carcinogenesis. 2009 Mar;30(3):494-9. doi: 10.1093/carcin/bgp017. Epub 2009 Jan 15.

PMID:
19147861
3.

Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.

Nagasaka T, Koi M, Kloor M, Gebert J, Vilkin A, Nishida N, Shin SK, Sasamoto H, Tanaka N, Matsubara N, Boland CR, Goel A.

Gastroenterology. 2008 Jun;134(7):1950-60, 1960.e1. doi: 10.1053/j.gastro.2008.02.094. Epub 2008 Mar 8.

4.

Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans.

Kumar K, Brim H, Giardiello F, Smoot DT, Nouraie M, Lee EL, Ashktorab H.

Clin Cancer Res. 2009 Feb 15;15(4):1155-61. doi: 10.1158/1078-0432.CCR-08-1029. Epub 2009 Feb 3.

5.

DNA content analysis of colorectal cancer defines a distinct 'microsatellite and chromosome stable' group but does not predict response to radiotherapy.

Fadhil W, Kindle K, Jackson D, Zaitoun A, Lane N, Robins A, Ilyas M.

Int J Exp Pathol. 2014 Feb;95(1):16-23. doi: 10.1111/iep.12070.

6.

Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.

Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS.

J Pathol. 2009 Dec;219(4):435-45. doi: 10.1002/path.2625.

PMID:
19824059
7.

Is KRAS mutation associated with interval colorectal cancers?

Shaukat A, Arain M, Anway R, Manaktala S, Pohlman L, Thyagarajan B.

Dig Dis Sci. 2012 Apr;57(4):913-7. doi: 10.1007/s10620-011-1974-6. Epub 2011 Dec 3.

PMID:
22138963
8.

MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers.

Choi YW, Song YS, Lee H, Yi K, Kim YB, Suh KW, Lee D.

Medicine (Baltimore). 2016 Apr;95(15):e3321. doi: 10.1097/MD.0000000000003321.

9.

KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer.

Nash GM, Gimbel M, Cohen AM, Zeng ZS, Ndubuisi MI, Nathanson DR, Ott J, Barany F, Paty PB.

Ann Surg Oncol. 2010 Feb;17(2):416-24. doi: 10.1245/s10434-009-0713-0. Epub 2009 Oct 8.

10.

Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways.

Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Ikeuchi H, Eshima K.

Eur J Cancer. 2011 Sep;47(13):1946-54. doi: 10.1016/j.ejca.2011.03.029. Epub 2011 Apr 29.

PMID:
21531130
11.

Mutations in the WTX-gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers.

Scheel SK, Porzner M, Pfeiffer S, Ormanns S, Kirchner T, Jung A.

BMC Cancer. 2010 Aug 9;10:413. doi: 10.1186/1471-2407-10-413.

12.

TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.

Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS.

Hum Pathol. 2007 Apr;38(4):614-20. Epub 2007 Jan 31.

PMID:
17270239
13.

Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.

Kure S, Nosho K, Baba Y, Irahara N, Shima K, Ng K, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2765-72. doi: 10.1158/1055-9965.EPI-09-0490. Epub 2009 Sep 29.

14.

Exclusive KRAS mutation in microsatellite-unstable human colorectal carcinomas with sequence alterations in the DNA mismatch repair gene, MLH1.

Zhao Y, Miyashita K, Ando T, Kakeji Y, Yamanaka T, Taguchi K, Ushijima T, Oda S, Maehara Y.

Gene. 2008 Nov 1;423(2):188-93. doi: 10.1016/j.gene.2008.07.014. Epub 2008 Jul 22.

PMID:
18692554
15.

Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.

Seth R, Crook S, Ibrahem S, Fadhil W, Jackson D, Ilyas M.

Gut. 2009 Sep;58(9):1234-41. doi: 10.1136/gut.2008.159137. Epub 2009 May 26.

PMID:
19474002
16.

Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.

Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A.

Pathol Res Pract. 2009;205(12):858-62. doi: 10.1016/j.prp.2009.07.010. Epub 2009 Aug 12.

PMID:
19679400
17.

Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.

Lee S, Cho NY, Choi M, Yoo EJ, Kim JH, Kang GH.

Pathol Int. 2008 Feb;58(2):104-13. doi: 10.1111/j.1440-1827.2007.02197.x.

PMID:
18199160
18.

Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS.

Iwamoto M, Kawada K, Nakamoto Y, Itatani Y, Inamoto S, Toda K, Kimura H, Sasazuki T, Shirasawa S, Okuyama H, Inoue M, Hasegawa S, Togashi K, Sakai Y.

J Nucl Med. 2014 Dec;55(12):2038-44. doi: 10.2967/jnumed.114.142927. Epub 2014 Nov 5.

19.

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F.

Br J Cancer. 2009 Aug 18;101(4):715-21. doi: 10.1038/sj.bjc.6605177. Epub 2009 Jul 14.

20.

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S.

JAMA. 2010 Oct 27;304(16):1812-20. doi: 10.1001/jama.2010.1535.

PMID:
20978259

Supplemental Content

Support Center